Style | Citing Format |
---|---|
MLA | Valipour M, et al.. "Recent Applications of Protoberberines As Privileged Starting Materials for the Development of Novel Broad-Spectrum Antiviral Agents: A Concise Review (2017-2023)." ACS Pharmacology and Translational Science, vol. 7, no. 1, 2024, pp. 48-71. |
APA | Valipour M, Zakeri Khatir Z, Abdollahi E, Ayati A (2024). Recent Applications of Protoberberines As Privileged Starting Materials for the Development of Novel Broad-Spectrum Antiviral Agents: A Concise Review (2017-2023). ACS Pharmacology and Translational Science, 7(1), 48-71. |
Chicago | Valipour M, Zakeri Khatir Z, Abdollahi E, Ayati A. "Recent Applications of Protoberberines As Privileged Starting Materials for the Development of Novel Broad-Spectrum Antiviral Agents: A Concise Review (2017-2023)." ACS Pharmacology and Translational Science 7, no. 1 (2024): 48-71. |
Harvard | Valipour M et al. (2024) 'Recent Applications of Protoberberines As Privileged Starting Materials for the Development of Novel Broad-Spectrum Antiviral Agents: A Concise Review (2017-2023)', ACS Pharmacology and Translational Science, 7(1), pp. 48-71. |
Vancouver | Valipour M, Zakeri Khatir Z, Abdollahi E, Ayati A. Recent Applications of Protoberberines As Privileged Starting Materials for the Development of Novel Broad-Spectrum Antiviral Agents: A Concise Review (2017-2023). ACS Pharmacology and Translational Science. 2024;7(1):48-71. |
BibTex | @article{ author = {Valipour M and Zakeri Khatir Z and Abdollahi E and Ayati A}, title = {Recent Applications of Protoberberines As Privileged Starting Materials for the Development of Novel Broad-Spectrum Antiviral Agents: A Concise Review (2017-2023)}, journal = {ACS Pharmacology and Translational Science}, volume = {7}, number = {1}, pages = {48-71}, year = {2024} } |
RIS | TY - JOUR AU - Valipour M AU - Zakeri Khatir Z AU - Abdollahi E AU - Ayati A TI - Recent Applications of Protoberberines As Privileged Starting Materials for the Development of Novel Broad-Spectrum Antiviral Agents: A Concise Review (2017-2023) JO - ACS Pharmacology and Translational Science VL - 7 IS - 1 SP - 48 EP - 71 PY - 2024 ER - |